Piśmiennictwo

1. Czech M. Farmakoekonomika jako narzędzie zarządzania w gospodarowaniu lekami w Polsce. Instytut Przedsiębiorczości i Samorządności. Warszawa 2006.
2. http://www.ispor.org/workpaper/modeling_methods/model-transparency-validation.asp dostęp 10.2010.
3. Czech M. Farmakoekonomika. Ekonomiczna ocena programów ochrony zdrowia. Oficyna Wydawnicza Politechniki Warszawskiej. Warszawa 2004.
4. Orlewska E. Rola i wartość modelowania w ocenie ekonomicznej programów zdrowotnych. Farmakoekonomika 2/2002.
5. E. Nowakowska. Farmakoekonomika. AM Poznań, Poznań 2010, wyd. 1.
6. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care. 2007 Jun;30(6): 1638-46.
7. The DCCT Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy:the Diabetes Control and ComplicationsTrial Research Group. Ann Intern Med. 122: 561–568, 1995.
8. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR: The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101: 671–679, 2001.
9. The DCCT Research Group: Effect of intensiva therapy on the development and progression of diabetic nephropathy In the Diabetes Control and Complications. Trial. Kidney Int 47: 1703–1720, 1995.
10. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316: 823– 828, 1998.
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observationalstudy. BMJ 321: 405–412, 2000.
12. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR: A model to estimate the lifetime health outcomes of patients with type 2 diabetes, UK Prospective Diabetes Study (UKPDS): the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47: 1747–1759, 2004.
13. http://www.dtu.ox.ac.uk dostęp 10.2010.
14. Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, Mathieu C, Bolinder B, Gerber R, Kvasz M, Bergemann R: Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes Technol Ther 8:219 –236, 2006.
15. Palmer J, Roze S, ValentineWJ et al.  Validation of the CORE Diabetes Model Against Epidemiologicaland Clinical Studies Current Medical Research And Opinion vol. 20, suppl 1, 2004, S27–S40.
16. http://archimedesmodel.com/] dostęp 10.2010.
17. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton- Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696, 2004.
18. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1-11.
19. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: and unavoidable fact of life. Health Econ 1997; 6: 217-27.